

**Thong Chai Institute of Medical Research**  
(Company Registration Number: 200311661W)  
(Registered under Companies Act, Chapter 50 and Charities Act, Chapter 37)

**AUDITED FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**



26 Eng Hoon Street Singapore 169776

Tel: 6533 7393 Fax: 6533 6831

[www.tanchan-cpa.com](http://www.tanchan-cpa.com)

**Thong Chai Institute of Medical Research**  
(Company Registration Number: 200311661W)

**AUDITED FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

| <b>Contents</b>                   | <b>Page</b> |
|-----------------------------------|-------------|
| Directors' Statement              | 1 - 2       |
| Independent Auditor's Report      | 3 - 5       |
| Statement of Financial Position   | 6           |
| Statement of Financial Activities | 7           |
| Statement of Changes in Funds     | 8           |
| Statement of Cash Flows           | 9           |
| Notes to the Financial Statements | 10 - 29     |

**Thong Chai Institute of Medical Research**  
**DIRECTORS' STATEMENT**  
**For the Financial Year Ended 31 December 2019**

---

The directors present their statement to the members together with the audited financial statements of Thong Chai Institute of Medical Research (the "Company") for the financial year ended 31 December 2019.

In the opinion of the directors,

- (a) the financial statements of the Company are drawn up so as to give a true and fair view of the financial position of the Company as at 31 December 2019, and of the financial performance, changes in funds, and cash flows of the Company for the financial year ended on that date; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

**DIRECTORS**

The directors of the Company in office at the date of this statement are:

|                             |                         |
|-----------------------------|-------------------------|
| Lim Guan Lee (Chairman)     |                         |
| Teo Kek Tjok @ Teo Kek Yeng |                         |
| Yeo Eng Koon                |                         |
| Low Theng Whee              | appointed on 25.04.2019 |
| Teo Kok Keong               |                         |
| Lim Tiang Chuan             | appointed on 25.04.2019 |
| Tan Tock Han                |                         |
| Khoo Boo Liat               |                         |
| Zheng HuangFang             | appointed on 25.04.2019 |
| Teo Chun Huat               |                         |
| Lee Hui Min                 | appointed on 25.04.2019 |
| Loh Kim Gek                 |                         |
| Lu Xiao Jian                |                         |
| Tan Hui Chin                | appointed on 25.04.2019 |
| Tan Quan Ming               | appointed on 25.04.2019 |
| Quek Yan Peng Leona         | appointed on 25.04.2019 |
| Na Yi Ting                  | appointed on 25.04.2019 |
| Tan Tze Kiat                | appointed on 25.04.2019 |
| Pang Weng Hou Edmund        | appointed on 25.04.2019 |

**ARRANGEMENTS TO ENABLE DIRECTORS TO ACQUIRE SHARES AND DEBENTURES**

Neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares or debentures of the Company or any other body corporate.

The Company has no share capital and its liabilities are limited by guarantee.

**Thong Chai Institute of Medical Research**

**DIRECTORS' STATEMENT  
For the Financial Year Ended 31 December 2019**

---

**DIRECTORS' INTEREST IN SHARES AND DEBENTURES**

No director who held office at the end of the financial year had interests in shares, share options, warrants or debentures of the Company, or of related corporations, either at the beginning of the financial year, or date of appointment if later, or end of the financial year.

**INDEPENDENT AUDITOR**

The independent auditor, Tan, Chan & Partners, has expressed its willingness to accept re-appointment as auditor.

On behalf of the Board of Directors,

Lim Guan Lee  
Director

Lim Tiang Chuan  
Director

Singapore

Date: 31 March 2020

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**Thong Chai Institute of Medical Research**  
For the Financial Year Ended 31 December 2019

---

### Report on the Audit of the Financial Statements

#### *Opinion*

We have audited the financial statements of Thong Chai Institute of Medical Research (the "Company"), which comprise the statement of financial position of the Company as at 31 December 2019, the statement of financial activities, statement of changes in funds, and statement of cash flows of the Company for the financial year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements of the Company are properly drawn up in accordance with the provisions of the Companies Act, Chapter 50 (the "Act"), the Charities Act, Chapter 37 and other relevant regulations (the "Charities Act and Regulations"), and Financial Reporting Standards in Singapore ("FRSs") so as to give a true and fair view of the financial position of the Company as at 31 December 2019, and of the financial performance, changes in funds, and cash flows of the Company for the financial year ended on that date.

#### *Basis for Opinion*

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority ("ACRA") Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Other Information*

Management is responsible for the other information. The other information comprises the Directors' Statement, but does not include financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**Thong Chai Institute of Medical Research**  
For the Financial Year Ended 31 December 2019

---

### *Responsibilities of Management and Directors for the Financial Statements*

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act, the Charities Act and Regulations and FRSS, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition, and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Company's financial reporting process.

### *Auditor's Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

**INDEPENDENT AUDITOR'S REPORT**  
**To the Members of**  
**Thong Chai Institute of Medical Research**  
**For the Financial Year Ended 31 December 2019**

---

*Auditor's Responsibilities for the Audit of the Financial Statements (Cont'd)*

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Report on Other Legal and Regulatory Requirements**

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act, and the Charities Act and Regulations.

During the course of our audit, nothing has come to our attention that causes us to believe that during the financial year:

- (a) the Company has not used the donation moneys in accordance with its objectives as required under Regulation 11 of the Charities (Institutions of a Public Character) Regulations; and
- (b) the Company has not complied with the requirement of Regulation 15 of the Charities (Institutions of a Public Character) Regulations.

  
**Tan, Chan & Partners**  
*Public Accountants and  
Chartered Accountants*

Singapore  
Date: 31 March 2020

**Thong Chai Institute of Medical Research**

**STATEMENT OF FINANCIAL POSITION**

**As at 31 December 2019**

|                                  | Note | 2019<br>\$              | 2018<br>\$<br>(Represented) |
|----------------------------------|------|-------------------------|-----------------------------|
| <b>ASSETS</b>                    |      |                         |                             |
| <b>Non-current asset</b>         |      |                         |                             |
| Plant and equipment              | 4    | -                       | -                           |
| <b>Current assets</b>            |      |                         |                             |
| Prepayment                       |      | 132                     | -                           |
| Other receivables                | 5    | 38,033                  | 43,645                      |
| Cash and bank balances           | 6    | 2,842,776               | 2,627,909                   |
|                                  |      | <u>2,880,941</u>        | <u>2,671,554</u>            |
| <b>Total assets</b>              |      | <u><u>2,880,941</u></u> | <u><u>2,671,554</u></u>     |
| <b>LIABILITY AND FUNDS</b>       |      |                         |                             |
| <b>Current liability</b>         |      |                         |                             |
| Other payables                   | 7    | 5,114                   | 15,839                      |
| <b>Funds</b>                     |      |                         |                             |
| <u>Unrestricted Fund</u>         |      |                         |                             |
| Non-designated:                  |      |                         |                             |
| -General Fund                    |      | 496,288                 | 415,060                     |
| Designated:                      |      |                         |                             |
| -Education Fund                  | 8    | 780,878                 | 641,994                     |
| <u>Restricted Fund</u>           |      |                         |                             |
| Medical Research Fund            | 9    | 1,598,661               | 1,598,661                   |
|                                  |      | <u>2,875,827</u>        | <u>2,655,715</u>            |
| <b>Total liability and funds</b> |      | <u><u>2,880,941</u></u> | <u><u>2,671,554</u></u>     |

The accompany notes form an integral part of the financial statements.





Thong Chai Institute of Medical Research

STATEMENT OF CHANGES IN FUNDS  
For the Financial Year Ended 31 December 2019

|  | Non-designated | Designated    | Restricted | Total     |
|--|----------------|---------------|------------|-----------|
|  | General        | Education     | Medical    | Funds     |
|  | fund           | fund          | Research   |           |
|  | \$             | \$            | fund       | \$        |
|  | (Note 8)       | (Note 9)      |            |           |
|  | (Represented)  | (Represented) |            |           |
| As at 01 January 2018  | 1,089,898      | -             | 1,598,661  | 2,688,559 |
| -As previously stated  | (721,844)      | 721,844       | -          | -         |
| -Prior financial year adjustment   | 368,054        | 721,844       | 1,598,661  | 2,688,559 |
| -As represented  |                |               |            |           |
| Deficit for the financial year, representing total comprehensive loss for the financial year   | (32,844)       | -             | -          | (32,844)  |
| -As previously stated  | 79,850         | (79,850)      | -          | -         |
| -Prior financial year adjustment   | 47,006         | (79,850)      | -          | (32,844)  |
| -As represented  |                |               |            |           |
| As at 31 December 2018 (As represented)  | 415,060        | 641,994       | 1,598,661  | 2,655,715 |
| Surplus for the financial year, representing total comprehensive income for the financial year | 81,228         | 138,884       | -          | 220,112   |
| As at 31 December 2019   | 496,288        | 780,878       | 1,598,661  | 2,875,827 |

The accompany notes form an integral part of the financial statements.

**Thong Chai Institute of Medical Research**  
**STATEMENT OF CASH FLOWS**  
**For the Financial Year Ended 31 December 2019**

|   | Note     | 2019<br>\$       | 2018<br>\$       |
|---|----------|------------------|------------------|
| <b>Operating activities</b>   |          |                  |                  |
| Surplus/(deficit) for the financial year                            |          | 220,112          | (32,844)         |
| <u>Adjustments for:</u>   |          |                  |                  |
| Depreciation of plant and equipment                                 | 4        | -                | 740              |
| Interest income   | 11       | (44,841)         | (33,078)         |
| Operating cash flows before working capital changes                 |          | 175,271          | (65,182)         |
| <u>Changes in working capital:</u>                                  |          |                  |                  |
| Prepayment  |          | (132)            | -                |
| Other receivables   |          | 1,080            | (20,088)         |
| Other payables  |          | (10,725)         | (3,779)          |
| Cash generated from/(used in) operations                            |          | 165,494          | (89,049)         |
| Interest received   |          | 49,373           | 22,218           |
| <b>Net cash flows generated from/(used in) operating activities</b> |          | <b>214,867</b>   | <b>(66,831)</b>  |
| <b>Net changes in cash and cash equivalents</b>                     |          | <b>214,867</b>   | <b>(66,831)</b>  |
| <b>Cash and cash equivalents at beginning of financial year</b>     |          | <b>2,627,909</b> | <b>2,694,740</b> |
| <b>Cash and cash equivalents at end of financial year</b>           | <b>6</b> | <b>2,842,776</b> | <b>2,627,909</b> |

The accompany notes form an integral part of the financial statements.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

**1. GENERAL INFORMATION**

Thong Chai Institute of Medical Research (the “Company”) is incorporated and domiciled in the Republic of Singapore, limited by guarantee and not having a share capital. The Company is registered as a charity under the Charities Act, Chapter 37 and is an approved Institution of Public Character (IPC) from 18 April 2018 to 17 April 2020. The IPC period has been extended from 18 April 2020 to 17 April 2022.

The registered office and its principal place of operation is located at 50 Chin Swee Road, #01-02, Thong Chai Building, Singapore 169874.

The principal activities of the Company are those of research and experimental development on medical technologies and other health services.

The financial statements of the Company for the financial year ended 31 December 2019 were authorised for issue by the Board of Directors on date of the Directors’ Statement.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**2.1 Basis of preparation**

The financial statements have been prepared in accordance with Financial Reporting Standards in Singapore (“FRSs”) under the historical cost convention, except as disclosed in the accounting policies below.

The financial statements of the Company are presented in Singapore dollars (“\$”).

**2.2 Adoption of new and amended standards and interpretations**

The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Company has adopted all the new and revised standards which are effective for annual financial periods beginning on or after 1 January 2019. The adoption of these new/revised standards and interpretations did not result in any substantial changes to the accounting policies of the Company, or have any material effect on the financial performance or position of the Company.

**2.3 Standards issued but not yet effective**

Certain new standards, amendments to standards and interpretations are issued but effective for annual financial periods beginning on or after 1 January 2020, and which the Company has not been early adopted in preparing these financial statements. None of these are expected to have a significant impact on the Company’s financial statements in the year of initial application.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.4 Functional currency**

Functional and presentation currency

The functional currency of the Company is determined to be Singapore dollar (“\$”), which is also the presentation currency of the Company’s financial statements.

Transactions and balances

Transactions arising in foreign currencies are recorded on initial recognition at the exchange rate approximating those ruling at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the end of the reporting period. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

Exchange differences arising on the settlement of monetary items or on translating monetary items at the end of the reporting period are recognised in statement of financial activities.

**2.5 Plant and equipment**

All items of plant and equipment are initially recorded at cost. Subsequent to initial recognition, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. The cost of plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to working condition for its intended use.

Depreciation is computed on a straight-line method over the estimated useful lives of the assets as follows:

|                        | <u>Estimated useful life</u> |
|------------------------|------------------------------|
| Computers              | 5 years                      |
| Furniture and fittings | 5 years                      |
| General equipment      | 10 years                     |
| Medical equipment      | 5 years                      |
| Office equipment       | 10 years                     |
| Signboard              | 5 years                      |

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use and no further charge for depreciation is made in respect of these assets.

The carrying values of plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The residual value, estimated useful lives and depreciation method are reviewed at each reporting period and adjusted prospectively, if appropriate.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.5 Plant and equipment (cont'd)**

An item of plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising from derecognition of the assets is included in statement of financial activities in the period that the assets are derecognised.

**2.6 Impairment of non-financial assets**

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment assessment for an asset is required, the Company makes an estimate of the asset's recoverable amount.

An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets. In assessing value in use, the estimated future cash flows expected to be generated by the asset are discounted to their present value. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and written down to its recoverable amount.

Impairment losses are recognised in statement of financial activities.

A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case, the carrying amount of the asset is increased to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss be recognised previously. Such reversal is recognised in statement of financial activities.

**2.7 Financial instruments**

**(a) Financial assets**

Initial recognition and measurement

Financial assets are recognised when, and only when the entity becomes party to the contractual provisions of the instruments.

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit and loss ("FVPL"), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in statement of financial activities.

Trade and other receivables are measured at the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third party, if the trade and other receivables do not contain a significant financing component at initial recognition.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.7 Financial instruments (cont'd)**

**(a) Financial assets (cont'd)**

Subsequent measurement

*Investments in debt instruments*

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the contractual cash flow characteristics of the asset. The three measurement categories for classification of debt instruments are amortised cost, fair value through other comprehensive income ("FVOCI") and FVPL. The Company only has debt instruments at amortised cost.

Financial assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in statement of financial activities when the assets are derecognised or impaired, and through the amortisation process.

Derecognition

A financial asset is derecognised where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or loss that had been recognised in other comprehensive income for debt instruments is recognised in statement of financial activities.

**(b) Financial liabilities**

Initial recognition and measurement

Financial liabilities are recognised when, and only when, the Company becomes a party to the contractual provisions of the financial instrument. The Company determines the classification of its financial liabilities at initial recognition.

All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable transaction costs.

Subsequent measurement

After initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in statement of financial activities when the liabilities are derecognised, and through the amortisation process.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

2.7 Financial instruments (cont'd)

(b) Financial liabilities (cont'd)

De-recognition

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in statement of financial activities.

2.8 Impairment of financial assets

The Company recognises an allowance for expected credit losses (“ECLs”) for all debt instruments not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is recognised for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).

For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment which could affect debtors’ ability to pay.

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.



**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.9 Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank, cash on hand and fixed deposits which are subject to an insignificant risk of changes in value.

**2.10 Provisions**

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated reliably.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

**2.11 Employee benefits**

Defined contribution plan

The Company makes contribution to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to this national pension scheme are recognised as an expense in the period in which the related service is performed.

Short-term benefits

All short-term benefits are recognised in statement of financial activities in the period in which the employees rendered their services to the Company.

**2.12 Income recognition**

Income is measured based on the consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to customers, excluding amounts collected on behalf of third parties.

Income is recognised when the Company satisfies a performance obligation by transferring a promised good or service to the customers, which is when the customers obtain control of the good or service. A performance obligation may be satisfied at a point in time or over time. The amount of income recognised is the amount allocated to the satisfied performance obligation.

*(a) Donations and Flag-day receipt*

Donations and flag-day receipt are recognised at the point in time.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

2.12 Income recognition (cont'd)

*(b) Course fees and seminar income*

Revenue from course fees and seminar income are recognised over a period of time based on the term of course and seminar.

*(c) Research and Development ("R&D") income*

Yi Shi Yuan Pte Ltd produces the BSYJ 120 & BSYJ 500 based on the prescriptions given by the Company which was specified in the collaboration agreement. R&D income is the payment received from Yi Shi Yuan Pte Ltd based on the sales volume sold multiplied with agreed rates (BSYJ 120 capsules @ \$8 & BSYJ 500 capsules @ \$24).

Revenue relating to research and development is recognised at the point in time.

*(d) Interest income*

Interest income is recognised using the effective interest method over a period of time.

*(e) Other miscellaneous income*

Other miscellaneous income is recognised at the point in time.

2.13 Contingencies

A contingent liability is:

- (a) a possible obligation that arises from past events whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or
- (b) a present obligation that arises from past events but is not recognised because:
  - (a) it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
  - (b) the amount of the obligation cannot be measured within sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company.

Contingent liabilities and assets are not recognised on the statement of financial position of the Company.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.14 Government grants**

Government grants are recognised when there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Where the grant relates to an asset, the fair value is recognised as deferred capital grant on the balance sheet and is amortised to statement of financial activities over the expected useful life of the relevant asset by equal annual instalments.

Where loans or similar assistance are provided by governments or related institutions with an interest rate below the current applicable market rate, the effect of this favourable interest is regarded as additional government grant.

**2.15 Related parties**

A related party is defined as follows:

- (a) A person or a close member of that person's family is related to the Company if that person:
  - (i) Has control or joint control over the Company;
  - (ii) Has significant influence over the Company; or
  - (iii) Is a member of the key management personnel of the Company or of a parent of the Company.
  
- (b) An entity is related to the reporting entity if any of the following condition applies:
  - (i) The entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to others);
  - (ii) One of the entities is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member);
  - (iii) Both entities are joint venture of the same third party;
  - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity;
  - (v) The entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company. If the Company is itself such a plan, the sponsoring employers are also related to Company;
  - (vi) The entity is controlled or jointly controlled by a person identified in (a);
  - (vii) A person identified in (a) (i) has significant influence over the entity or is a member of the key management personnel of the entity (of or a parent of the entity).

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**2.16 Key management personnel**

Key management personnel of the Company are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company whether directly or indirectly. The directors are considered as key management personnel of the Company.

**3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES**

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of the revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of reporting period. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

Management is of the opinion that there is no significant judgement made in applying accounting policies, and no estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period.

**Thong Chai Institute of Medical Research**

**NOTES TO THE FINANCIAL STATEMENTS  
For the Financial Year Ended 31 December 2019**

**4. PLANT AND EQUIPMENT**

|                                 | Note | Computers<br>\$ | Furniture<br>and fittings<br>\$ | General<br>equipment<br>\$ | Medical<br>equipment<br>\$ | Office<br>equipment<br>\$ | Signboard<br>\$ | Total<br>\$   |
|---------------------------------|------|-----------------|---------------------------------|----------------------------|----------------------------|---------------------------|-----------------|---------------|
| <b>Cost</b>                     |      |                 |                                 |                            |                            |                           |                 |               |
| As at 01 January 2018,          |      |                 |                                 |                            |                            |                           |                 |               |
| 31 December 2018 and            |      |                 |                                 |                            |                            |                           |                 |               |
| <b>31 December 2019</b>         |      | <b>16,666</b>   | <b>280</b>                      | <b>8,932</b>               | <b>150</b>                 | <b>1,554</b>              | <b>2,170</b>    | <b>29,752</b> |
| <b>Accumulated depreciation</b> |      |                 |                                 |                            |                            |                           |                 |               |
| As at 01 January 2018           |      | 15,926          | 280                             | 8,932                      | 150                        | 1,554                     | 2,170           | 29,012        |
| Depreciation                    | 13   | 740             | -                               | -                          | -                          | -                         | -               | 740           |
| As at 31 December 2018          |      |                 |                                 |                            |                            |                           |                 |               |
| <b>and 31 December 2019</b>     |      | <b>16,666</b>   | <b>280</b>                      | <b>8,932</b>               | <b>150</b>                 | <b>1,554</b>              | <b>2,170</b>    | <b>29,752</b> |
| <b>Net carrying amount</b>      |      |                 |                                 |                            |                            |                           |                 |               |
| As at 31 December 2018          |      | -               | -                               | -                          | -                          | -                         | -               | -             |
| <b>and 31 December 2019</b>     |      | <b>-</b>        | <b>-</b>                        | <b>-</b>                   | <b>-</b>                   | <b>-</b>                  | <b>-</b>        | <b>-</b>      |

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

**5. OTHER RECEIVABLES**

|                                     | 2019          | 2018          |
|-------------------------------------|---------------|---------------|
|                                     | \$            | \$            |
| Fixed deposits interest receivables | 19,025        | 23,557        |
| Sundry receivables                  | 19,008        | 20,088        |
|                                     | <u>38,033</u> | <u>43,645</u> |

Non-trade sundry receivables are unsecured, interest-free and receivable on demand.

**6. CASH AND BANK BALANCES**

|                | 2019             | 2018             |
|----------------|------------------|------------------|
|                | \$               | \$               |
| Cash at bank   | 364,616          | 199,332          |
| Cash on hand   | 383              | 173              |
| Fixed deposits | 2,477,777        | 2,428,404        |
|                | <u>2,842,776</u> | <u>2,627,909</u> |

Fixed deposits are placed with financial institutions for a period of 6 to 12 months (2018: 12 months) and earn interest rates at the respective deposit rates. The average interest rates were 1.91% (2018: 1.36%) per annum and mature approximately less than 1 to 4 months (2018: 2 to 7 months) from the end of the reporting period.

**7. OTHER PAYABLES**

|                            | 2019         | 2018          |
|----------------------------|--------------|---------------|
|                            | \$           | \$            |
| Accrued operating expenses | 5,034        | 15,839        |
| Advance membership fee     | 80           | -             |
|                            | <u>5,114</u> | <u>15,839</u> |

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

**8. EDUCATION FUND**

Education Fund is established to support the Nanyang Technological University students and Traditional Chinese Medicine Physicians to enable them to continue with their education at universities. It's also used for expenses incurred for lecture fee, and other related expenses for further education purposes.

|  | Note  | 2019<br>\$       | 2018<br>\$<br>(Represented) |
|--|-------|------------------|-----------------------------|
| At the beginning of the financial year   |       | 641,994          | 721,844                     |
| Income received for the financial year   |       | 240,000          | -                           |
| Expenses incurred for the financial year | 12,13 | <u>(101,116)</u> | <u>(79,850)</u>             |
| At the end of the financial year         |       | <u>780,878</u>   | <u>641,994</u>              |

**9. MEDICAL RESEARCH FUND**

|   | 2019<br>\$       | 2018<br>\$       |
|---|------------------|------------------|
| At the beginning/ end of the financial year | <u>1,598,661</u> | <u>1,598,661</u> |

The fund was originally established by Singapore Thong Chai Medical Institution for the medical research and further education and training for Traditional Chinese Physicians in the field of Traditional Chinese Medicine.

Thong Chai Institute of Medical Research was incorporated to undertake the role for the designated purpose. Accordingly, pursuant to the constitution and rules, the fund was transferred on 23 October 2008.





**Thong Chai Institute of Medical Research**

**NOTES TO THE FINANCIAL STATEMENTS**  
For the Financial Year Ended 31 December 2019

**11. OTHER INCOME**

|                                | Non-designated |          | Designated     |          | Total funds   |               |
|--------------------------------|----------------|----------|----------------|----------|---------------|---------------|
|                                | General fund   | 2019     | Education fund | 2019     | 2019          | 2018          |
|                                | \$             | \$       | \$             | \$       | \$            | \$            |
|                                |                |          |                |          |               |               |
| Fixed deposits interest income | 44,841         | -        | -              | -        | 44,841        | 33,078        |
| Membership fees                | 1,210          | -        | -              | -        | 1,210         | 600           |
| Special Employment Credit      | 132            | -        | -              | -        | 132           | 138           |
| Temporary Employment Credit    | -              | -        | -              | -        | -             | 206           |
| e2i Training Grant             | -              | -        | -              | -        | -             | 2,240         |
| Wage Credit Scheme             | -              | -        | -              | -        | -             | 189           |
|                                | <b>46,183</b>  | <b>-</b> | <b>-</b>       | <b>-</b> | <b>46,183</b> | <b>36,451</b> |

Thong Chai Institute of Medical Research

NOTES TO THE FINANCIAL STATEMENTS  
For the Financial Year Ended 31 December 2019

12. COST OF CHARITABLE ACTIVITIES

|  | 2019                              |                                 | 2018                              |                                 |
|--|-----------------------------------|---------------------------------|-----------------------------------|---------------------------------|
|  | Non-designated<br>General<br>fund | Designated<br>Education<br>fund | Non-designated<br>General<br>fund | Designated<br>Education<br>fund |
|  | \$                                | \$                              | \$                                | \$                              |
|  |                                   | (Note 8)                        |                                   | (Note 8)                        |
|  | 2019                              | 2019                            | 2018                              | 2018                            |
|  |                                   |                                 |                                   |                                 |
|  |                                   | Total<br>funds                  | Total<br>funds                    | Total<br>funds                  |
| Compensation claim expense             | 11,445                            | -                               | -                                 | -                               |
| Lecture fees                           | -                                 | 3,173                           | -                                 | 2,665                           |
| Scholarships                           | -                                 | 40,000                          | -                                 | 35,000                          |
| Sponsorships                           | -                                 | 57,564                          | -                                 | 42,185                          |
| Staff salaries and other related costs | 24,189                            | -                               | 97,792                            | -                               |
|  | <b>35,634</b>                     | <b>100,737</b>                  | <b>97,792</b>                     | <b>79,850</b>                   |
|  |                                   | <b>136,371</b>                  |                                   | <b>177,642</b>                  |

Thong Chai Institute of Medical Research

NOTES TO THE FINANCIAL STATEMENTS  
For the Financial Year Ended 31 December 2019

13. GOVERNANCE AND ADMINISTRATIVE COSTS

|  | 2019                              |                                 | 2018                              |                                 |
|--|-----------------------------------|---------------------------------|-----------------------------------|---------------------------------|
|  | Non-designated<br>General<br>fund | Designated<br>Education<br>fund | Non-designated<br>General<br>fund | Designated<br>Education<br>fund |
|  | \$                                | \$                              | \$                                | \$                              |
|  |                                   | (Note 8)                        |                                   | (Note 8)                        |
| Advertisement                          | 1,288                             | -                               | 730                               | -                               |
| Audit fee                              | 4,354                             | -                               | 3,884                             | -                               |
| Bank charges                           | 4,789                             | -                               | 460                               | -                               |
| Computer maintenance fee               | -                                 | -                               | 88                                | -                               |
| Depreciation of plant and equipment    | -                                 | -                               | 740                               | -                               |
| Entertainment                          | 3,534                             | 379                             | 415                               | -                               |
| General expenses                       | 2,658                             | -                               | 186                               | -                               |
| Membership fee                         | -                                 | -                               | 144                               | -                               |
| Postage, printing and stationery       | 4,422                             | -                               | 189                               | -                               |
| Royalty fees                           | 3,748                             | -                               | 3,122                             | -                               |
| Secretarial fee                        | 1,300                             | -                               | 400                               | -                               |
| Service fee                            | 4,465                             | -                               | 342                               | -                               |
| Staff salaries and other related costs | -                                 | -                               | 4,777                             | -                               |
| Telephone charges                      | 173                               | -                               | 184                               | -                               |
| Transportation                         | -                                 | -                               | 71                                | -                               |
| Travelling expenses                    | 669                               | -                               | 551                               | -                               |
| Website design and maintenance         | 2,400                             | -                               | -                                 | -                               |
|  | 33,800                            | 379                             | 16,283                            | -                               |
|  |                                   |                                 |                                   | 16,283                          |
|  |                                   |                                 |                                   | \$                              |
|  |                                   |                                 |                                   | \$                              |

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

**14. DONATIONS**

|  | <b>2019</b>           | <b>2018</b>          |
|--|-----------------------|----------------------|
|  | \$                    | \$                   |
| Tax exempt donations                     | 250,580               | 20,420               |
| Non-tax exempt donations                 | <u>53,082</u>         | <u>38,190</u>        |
|  | <u><b>303,662</b></u> | <u><b>58,610</b></u> |
| The donations were allocated as follows: |                       |                      |
| -Donations                               | 250,340               | 19,330               |
| -Flag-day receipt                        | <u>53,322</u>         | <u>39,280</u>        |
|  | <u><b>303,662</b></u> | <u><b>58,610</b></u> |

The Company enjoys a concessionary tax treatment whereby qualifying donors are granted tax deduction for the donations made to the Company.

During the reporting year, the Company has issued tax exempt receipts for donations collected amounting to \$250,580 (2018: \$20,420).

**15. 30/70 FUND-RAISING EFFICIENCY RATIO**

|                                      | <b>2019</b>        | <b>2018</b>        |
|--------------------------------------|--------------------|--------------------|
|                                      | \$                 | \$                 |
| Net proceeds from fund-raising event | <u>53,322</u>      | <u>39,280</u>      |
| Cost of fund-raising event           | <u>4,683</u>       | <u>1,936</u>       |
| Fund-raising efficiency ratio        | <u><b>8.8%</b></u> | <u><b>4.9%</b></u> |

The Company had kept the fund-raising efficiency ratio below 30%. For fund-raising done via sale of merchandise, only the net proceeds which is the gross amount received from sale of merchandise less cost of relevant goods, will be treated as receipts. No fund-raising done via sale of merchandise held during the financial year.

**16. TAXATION**

The Company is registered as an exempt charity under the Charities Act, Chapter 37 with effect from 05 January 2004. By virtue of section 13 (1) (zm) of the Income Tax Act Cap 134, the Company is exempted from income tax.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

**17. RELATED PARTY TRANSACTIONS**

In addition to the related party transactions disclosed elsewhere in the financial statements, the Company carried out the following transactions with the related parties on terms between the parties during the financial year:

Compensation to key management personnel

|                              | 2019          | 2018         |
|------------------------------|---------------|--------------|
|                              | \$            | \$           |
| Directors' remuneration:     |               |              |
| - Salaries and bonuses       | 2,657         | 2,657        |
| - CPF contribution           | 240           | 240          |
| - Sponsorship                | 19,727        | -            |
| - Lecture fee                | 120           | -            |
| - Clinical teaching expenses | 480           | -            |
| - Royalty fee                | 2,624         | 2,185        |
|                              | <u>25,848</u> | <u>5,082</u> |

**18. MEMBERS GUARANTEE**

The liability of each ordinary member and physician member is limited to \$50 and \$10 respectively while he or she is a member, or within one year after he or she ceases to be a member.

As at the end of the reporting period, the Company has 63 (2018: 54) members.

**19. FINANCIAL INSTRUMENTS**

At the reporting date, the aggregate carrying amounts of financial assets at amortised cost and financial liabilities at amortised cost were as follows:

|  | Note | 2019             | 2018             |
|--|------|------------------|------------------|
|  |      | \$               | \$               |
| <u>Financial assets</u>                                |      |                  |                  |
| Other receivables                                      | 5    | 38,033           | 43,645           |
| Cash and bank balances                                 | 6    | 2,842,776        | 2,627,909        |
| <b>Financial assets carried at amortised cost</b>      |      | <u>2,880,809</u> | <u>2,671,554</u> |
| <u>Financial liabilities</u>                           |      |                  |                  |
| Other payables   | 7    | 5,114            | 15,839           |
| <i>Less: Advance membership fee</i>                    |      | (80)             | -                |
| <b>Financial liabilities carried at amortised cost</b> |      | <u>5,034</u>     | <u>15,839</u>    |

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

---

**20. FAIR VALUE OF ASSETS AND LIABILITIES**

No financial assets or liabilities were measured at fair value as at financial year end.

The carrying amounts of financial assets and liabilities on the statement of financial position approximate their respective fair values due to the relatively short-term maturity of these financial instruments.

The directors consider that the carrying amounts of financial assets and liabilities recorded at amortised cost in the financial statements approximate their fair values.

**21. FUNDS MANAGEMENT**

The primary objective of the Company's funds management is to ensure that the funding from members and other sources are properly managed and used to support its operations.

The Company manages its funds structure and makes adjustments to it, in light of changes in economic conditions. No changes were made to the objectives, policies or processes during the financial years ended 31 December 2019 and 2018 respectively.

The Company is not subjected to externally imposed capital requirements.

**22. FINANCIAL RISK MANAGEMENT**

The key financial risk faced by the Company is liquidity risk.

The Board of Directors is responsible for setting the objectives and underlying principles of financial risk management for the Company. The management team then establishes the detailed policies such as risk identification, measurement and exposure limits.

The finance personnel measure actual exposures against the limits set and prepare regular reports for the review of the management team and the Board of Directors. The information presented below is based on information received by key management.

Liquidity risk

Liquidity risk is the risk that the Company may encounter difficulties to settle or meet its financial obligations due to shortage of available funds. The Company's objective is to maintain sufficient level of cash and bank balances, and internally generated cash flows to finance its activities. The Company actively manages its operating cash flows and availability of funding so as to ensure that all repayment and funding needs are met.

All financial liabilities at the end of the reporting period are repayable within one year from the reporting date.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2019**

**23. COMPARATIVE FIGURES**

Certain reclassifications have been made to the prior year financial statements to enhance comparability with current year's financial statements. As a result, certain line items have been amended on the face of the statement of financial position and statement of financial activities.

|   | As<br>previously<br>stated<br>\$ | Reclassification<br>of comparative<br>figures, effects<br>of matters<br>\$ | As<br>represented<br>\$ |
|---|----------------------------------|--|-------------------------|
| <b><u>Statement of financial position</u></b>   |                                  |  |                         |
| - General fund                                  | 1,057,054                        | (641,994)  | 415,060                 |
| - Education fund                                | -                                | 641,994  | 641,994                 |
|   | <u>1,057,054</u>                 | <u>-</u>   | <u>1,057,054</u>        |
| <b><u>Statement of financial activities</u></b> |                                  |  |                         |
| <b><u>Cost of charitable activities</u></b>     |                                  |  |                         |
| - General fund                                  | 177,642                          | (79,850)   | 97,792                  |
| - Education fund                                | -                                | 79,850   | 79,850                  |
|   | <u>177,642</u>                   | <u>-</u>   | <u>177,642</u>          |

